Skip to main content
Premium Trial:

Request an Annual Quote

Compugen to Divest Bioccelerator Line to Biocceleration

NEW YORK, July 17 - Compugen intends to sell its Bioccelerator product line to Biocceleration next month in exchange for "certain fixed payments" and future royalty rights. 
 

"By transferring the Bioccelerator product line, we are strengthening Compugen's focus on our two primary commercialization channels: high-end platforms and services that we offer to leading biopharmaceutical companies, and discoveries based on our own internal research," said Mor Amitai, president and CEO of Compugen.

 

According to Compugen, the Bioccelerator line was designed to accelerate similarity searches in nucleotide and protein databases.

Biocceleration is a bioinformatics company established by a group of private investors, and is headed by Simchon Faigler, who co-founded Compugen in 1993.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.